Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
All News
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week on the RheumNow podcast.
Treat-to-Target has Excellent 10-Year Outcomes in RA
Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said.
‘Strong’ data in #myositis #0904 #Efgartigimod ⬇️Igs &#Abs LB +ph3 #RCT -👍on Wed #0905 #nipocalimab in #IIM also #FcRn #0906 #ruxolitinib ⬆️#survival in severe #MDA5 - but not RCT #0907 +RCT IIM #Brepocitinib ☑️clinical remission ☑️HAQ ☑️LDA #ACR26 #ACRbest @RheumNow
